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Abstract
Background: Although classified as metal oxides, cobalt monoxide (CoO) and lanthanum oxide (La2O3) nanoparticles,
as representative transition and rare earth oxides, exhibit distinct material properties that may result in different
hazardous potential in the lung. The current study was undertaken to compare the pulmonary effects of aerosolized
whole body inhalation of these nanoparticles in mice.
Results: Mice were exposed to filtered air (control) and 10 or 30 mg/m3 of each particle type for 4 days and
then examined at 1 h, 1, 7 and 56 days post-exposure. The whole lung burden 1 h after the 4 day inhalation
of CoO nanoparticles was 25 % of that for La2O3 nanoparticles. At 56 days post exposure, < 1 % of CoO nanoparticles
remained in the lungs; however, 22–50 % of the La2O3 nanoparticles lung burden 1 h post exposure was retained at
56 days post exposure for low and high exposures. Significant accumulation of La2O3 nanoparticles in the
tracheobronchial lymph nodes was noted at 56 days post exposure. When exposed to phagolysosomal simulated fluid,
La nanoparticles formed urchin-shaped LaPO4 structures, suggesting that retention of this rare earth oxide nanoparticle
may be due to complexation of cellular phosphates within lysosomes. CoO nanoparticles caused greater lactate
dehydrogenase release in the bronchoalveolar fluid (BALF) compared to La2O3 nanoparticles at 1 day post
exposure, while BAL cell differentials indicate that La2O3 nanoparticles generated more inflammatory cell
infiltration at all doses and exposure points. Histopathological analysis showed acute inflammatory changes at
1 day after inhalation of either CoO or La2O3 nanoparticles. Only the 30 mg/m3 La2O3 nanoparticles exposure
caused chronic inflammatory changes and minimal fibrosis at day 56 post exposure. This is in agreement with
activation of the NRLP3 inflammasome after in vitro exposure of differentiated THP-1 macrophages to La2O3
but not after CoO nanoparticles exposure.
Conclusion: Taken together, the inhalation studies confirmed the trend of our previous sub-acute aspiration
study, which reported that CoO nanoparticles induced more acute pulmonary toxicity, while La2O3 nanoparticles
caused chronic inflammatory changes and minimal fibrosis.
Keywords: Nanoparticles, Metal oxides, Pulmonary response, In vivo, Mouse
Abbreviations: A549, Adenocarcinomic Human Alveolar Base Epithelial Cells; AOPs, Adverse Outcome Pathways;
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Background
Nanotechnology is perceived as one of the most notable
research achievements of this century. Engineered nanoparticles are currently being used in many industrial areas.
Particularly, metal oxide nanoparticles are an important
class of engineered nanomaterials with broad applications
in many industries. From a health perspective, previous
studies have shown that some metal oxide nanoparticles
can induce adverse effects at organ, tissue, cellular, protein, and gene levels [1]. A number of transition metal
oxide nanoparticles exhibit semi-conductor properties in
which the material band gap plays a role in electron transfer to and from biological redox components. This can
lead to the generation of adverse health effects due to the
generation of oxygen radicals and oxidative stress [2]. According to the band gap theory, electron transfer between
metal oxide nanoparticles and aqueous biological reactants is dependent on an overlap of the metal oxide band
gap energy level with a biological equivalent, known as the
cellular redox potential [3]. The accompanying electron
transfer from the nanoparticle surface to a series of redox
couples that reconstitute of biological redox potential can
result in the generation of reactive oxygen species (ROS),
disturbance of cellular redox homeostasis, and oxidative
damage to DNA or proteins [4, 5]. Cobalt monoxide
(CoO) and lanthanum oxide (La2O3) differ with respect to
their biological properties. While for the transition metal
oxide, CoO, the conduction band energy overlaps with the
cellular biological redox potential, there is no similar
overlap for the rare earth oxide, La2O3 [3]. In contrast, La2O3 (and other rare earth oxide) nanoparticles
exhibit non-oxidative surface reactivity that may come
into play in a biological environment with the possibility to generate hazard through complexation of cellular phosphate groups in the lysosome [6]. In brief,
this study addresses how phosphate complexation of
La nanoparticles in the acidic environment of the
phagolysosome can induce lysosomal membrane damage, activation of the NRLP3 inflammasome, and IL1β production [6].

Previously, we investigated CoO and La2O3 nanoparticleinduced cellular toxicity, production of superoxide radicals, and alterations in gene expression related to oxidative stress and cellular death in human small airway
epithelial cells (SAEC) [7]. Results in that study showed
that CoO nanoparticles caused more adverse effects
than La2O3 nanoparticles, using cytotoxicity assays in
SAEC. Moreover, CoO nanoparticles produced more
superoxide radicals and induced greater induction of
total global tyrosine and threonine phosphorylation in
SAEC compared to the La2O3 nanoparticle. Profiling of
oxidative stress pro-apoptotic gene expression demonstrated that CoO nanoparticles induced significant
transcriptional activation of PTGS2(COX2), NOS2,
SOD3, and MT3 genes in SAEC. These results indicate
that different modes of action could be involved in mediating cellular toxicity by CoO and La2O3 nanoparticles.
Similar observations regarding the cytotoxic potential of
CoO and La2O3 nanoparticles have been reported by
other laboratories. For instance, CoO nanoparticles have
been shown to be cytotoxic in human lymphocytes, alveolar A549, and bronchial BEAS-2B epithelial cells [8, 9].
However, Lim et al. showed that La2O3 nanoparticles were
cytotoxic at high doses and prolonged exposure times in
RAW264.7 and A549 cells [10]. In addition, our recent
study indicates that La2O3 nanoparticles (50 μg/mL) induced lysosomal damage, cathepsin B release, and IL-1β
production after in vitro exposure of differentiated THP-1
macrophages for 6 h [6]. Taken together, these data
demonstrate that CoO and La2O3 nanoparticles have
the potential to induce different biological effects in
vivo, based on different modes of action after pulmonary exposure. For instance, in oropharyngeal aspiration
studies in mice, we observed more acute inflammation
with CoO and La2O3 nanoparticles which is in agreement with in vitro cytotoxicity results [3]. However, in
a longer term (21 day post exposure) La2O3 aspiration
study, we observed elevation of fibrogenic factors in
bronchoalveolar lavage fluid (BALF) and increased lung
collagen in mice; which is in agreement with in vitro
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activation of the NLRP3 inflammasome in cellular studies [6].
The objective of the present study was to explore the
pulmonary effects of CoO and La2O3 nanoparticles in
mice for up to 56 days after whole-body inhalation exposure, which is more representative of possible human
exposures than a bolus dose administration. The rationale for this study was to determine whether the different
modes of action of CoO and La2O3 nanoparticles could
be seen to elicit different types of information after short
and longer-term exposure as a reflection of the effect of
the bandgap overlap and pro-oxidative properties of the
former particle type versus activation of the NRLP3
inflammasome by La2O3 nanoparticles.
BALF and pulmonary tissue were analyzed to determine if these nanomaterials have overlapping or contrasting features that can be related to inhalation
exposure at low and high doses. We demonstrate that
there are indeed differences in the pulmonary responses
to CoO and La2O3 nanoparticles in the induction of
acute vs. chronic pulmonary responses. Such differences
are reflective of adverse outcome pathways (AOPs) for
these materials [11], which we previously established by
our cellular and bolus aspiration studies [3, 6, 7]. The results of this inhalation study support the usefulness of a
tiered approach including mechanistically relevant in
vitro screening tests and bolus in vivo exposures in predicting pulmonary responses during inhalation exposures to nanoparticles [11].

Methods
Nanoparticles

CoO nanoparticles were purchased from SkySpring Nanomaterials (Houston, TX) and La2O3 nanoparticles were
purchased from Nanostructured & Amorphous Materials,
Inc. (Houston, TX). The physicochemical characteristics
of these particles are given in Table 1 [3, 7].
Acellular transformation of La2O3 nanoparticles in
phagolysosomal simulated fluid (PSF)

La2O3 nanoparticles were suspended in 10 mL of phagolysosomal simulated fluid (PSF) (142 mg/L Na2HPO4,
6.65 g/L NaCl, 62 mg/L Na2SO4, 29 mg/L CaCl2 • 3
Table 1 Physiochemical Characterization of CoO and La2O3
Nanoparticles
Property

Characterization Nanoparticles
Technique
CoO
La2O3

Size

TEM

72 ± 16 nm

25 ± 5 nm
Hexagonal

Crystal Structure

XRD

Cubic

Morphology

TEM

Agglomerate Agglomerate

Size in DI H2O

DLS

185 ± 12 nm

211 ± 11 nm

32 ± 4 mV

58 ± 7 mV

Zeta potential in DI H2O Zeta PALS

H2O, 250 mg/L glycine, 8.09 g/L potassium phthalate,
pH 4.5) at a concentration of 50 μg/mL, and sonicated at
32 W for 15 s. Following incubation at 37 °C for 24 h, the
particle suspensions were centrifuged at 15,000 rpm for
10 min. The pellets were collected, thoroughly washed
with DI H2O and dried for further use. The composition
and morphology of PSF-treated La2O3 nanoparticles were
characterized by XRD (Panalytical X’Pert Pro diffractometer, Cu KR radiation) and TEM (JEOL 1200 EX, accelerating voltage 80 kV), respectively.
Cathepsin B release and IL-1β production in THP-1 cells

THP-1 cells were differentiated into macrophages as described previously [6]. Briefly, aliquots of 5 × 104 cells
were seeded in 0.1 mL complete medium and primed with
1 μg/mL of phorbol 12-myristate acetate (PMA) overnight
in 96-well plates (Corning; Corning, NY, USA). These
macrophages were treated with CoO or La2O3 nanoparticles (50 μg/mL) in complete RPMI 1640 for 6 h, followed
by washing in phosphate-buffered saline (PBS). Cells were
stained with the cathepsin B substrate, Magic Red (ImmunoChemistry Technologies), for 1 h and fixed in 4 %
paraformaldehyde for 20 min. Following washing in PBS,
nuclei were stained with Hoechst 33342 for 1 h. The cells
were visualized under a confocal microscope (Leica Confocal SP2 1P/FCS). High magnification images were obtained under the 63× objective and the lysosomal vs.
cytosolic staining of cathepsin B noted as an indication of
particle-induced lysosomal damage.
IL-1β production was detected in the THP-1 differentiated macrophage culture medium, using a human IL1β ELISA Kit (BD; San Jose, CA, USA). Briefly, cells (5 ×
104 cells) were treated with 0 – 100 μg/mL CoO or
La2O3 nanoparticles suspended in complete RPMI 1640
that also contained 10 ng/mL of lipopolysaccharide
(LPS) to induce production of pro-IL-1β. The nanoparticle suspensions were sonicated in media containing 10 %
fetal bovine serum with a Sonics & Materials probe at
32 W for 15 s before adding to the cells. As reported
previous studies [3], acellular suspensions of CoO nanoparticles generated significant levels of reactive oxygen
species (ROS) measured as DCF fluorescence. ROS generation was not affected by sonication (Additional file 1:
Figure S1). In contrast, suspensions of La2O3 nanoparticles did not generate ROS either before or after sonication (Additional file 1: Figure S1). It should be noted
that the densities of CoO and La2O3 nanoparticles and
their resultant sedimentation rates in cell culture media
are similar. Calculations indicate that 80 % of the nanoparticles would settle on the cells after 24 h.
Animals

Eight week old male, pathogen-free C57BL/6 J mice were
obtained from Jackson Laboratories (Bar Harbor, ME).
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Mice were housed individually and allowed to acclimate
for 1 week in an AAALAC-accredited animal facility and
4 days within the chambers, which were used later for
whole-body inhalation exposure. After exposure, animal
weight was monitored weekly to assess the health of the
animals. All procedures performed on animals were approved by the NIOSH Institutional Animal Care and Use
Committee (IACUC).
Mice were assigned to exposure groups using a randomized complete block design. Mice were exposed to
either CoO or La2O3 nanoparticles, or air control. Mice
were used to determine whole lung deposition immediately post exposure, lung clearance, inflammatory and
damage markers in bronchoalveolar lavage, or histopatholoic responses. Animals were exposed to a low
dose (10 mg/m3) or high dose (30 mg/m3) for 4 days at
6 h/day and were sacrificed at 1 h and 1, 7, or 56 days
post exposure. At 1 h post exposure, animals were taken
for lung burden (n = 5 mice per each CoO and La2O3
exposure group and air control). At 1, 7, and 56 days
post exposure, animals were analyzed for bronchoalveolar lavage and histopathology (n = 12 for each CoO and
La2O3 exposure group and n = 24 for air control). At
56 days post exposure, mice were taken for analysis of
nanoparticle clearance from the mouse lung (n = 5 mice
per each CoO and La2O3 nanoparticle exposure group).
Inhalation exposure system

The CoO and La2O3 nanoparticles aerosols were generated using an acoustical-based, computer controlled,
whole body inhalation system as described previously
[12]. In brief, the inhalation exposure system combines air flow controllers, aerosol particle monitors,
data acquisition devices, and custom software with
automated feedback control to achieve constant and
repeatable exposure chamber temperature, relative humidity, pressure, aerosol concentration, and particle
size distributions as previously described [12–15]. The
system is capable of producing airborne particles continuously for long periods of time with minimal
fluctuations.
In this study, the CoO and La2O3 nanoparticles
aerosol mass concentrations within the exposure
chamber were continuously monitored with a Data
RAM (DR-40000 Thermo Electron Co, Franklin, MA),
and gravimetric determinations (37 mm cassettes with
0.45 μm pore-size Teflon filters) were used to calibrate
and verify the Data RAM readings each day. The target
concentrations for both CoO and La2O3 were 10 mg/m3
for a duration of 6 h/day for 4 consecutive days (low dose),
or 30 mg/m3 for a duration of 6 h/day for 4 consecutive
days (high dose). These aerosol concentrations and exposure durations were chosen to yield lung burdens in the
range of our previous aspiration study [6]. Each exposure
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group had a corresponding clean air control exposed
group.
The mass-based particle size distribution of the nanoparticle aerosol in the exposure chamber was determined by a cascade impactor (MOUDI Model 110-R,
MSP Corp., Shoreview, MN). Exposure chamber air
(10 L/min) was mixed with filtered air (20 L/min) and
fractionated onto 10 size stages of the impactor, representing 10 size ranges from 56 nm to 18 μm. Mass median
aerodynamic diameter was obtained from these data.
The count-based particle size distribution of particles
within the exposure chamber was measured using a
Scanning Mobility Particle Sizer (SMPS model, TSI Inc.,
Shoreview, MN) at a sampling rate of 0.3 L/min. Count
median aerodynamic diameter was obtained from these
data assuming a spherical particle shape.
Aerosol samples from the exposure chamber were collected on 25 mm polycarbonate filters with 0.2 μm pores
(EMD-Millipore, Billercia, MA) at a rate of 1 L/min to
obtain particle samples for further analysis by field emission scanning electron microscopy (FESEM) as described previously [12, 14].
Lung burden and lung clearance

Mice were euthanized after 1 h or 56 days post-exposure
by intraperitoneal (i.p.) injection of sodium pentobarbital
and exsanguination. The 1 h analysis time was included to
determine lung burden immediately following the 4 day
inhalation exposure. This would provide information concerning the rapid clearance of particles from the conducting zone during the 4 days of inhalation exposure. The
differences in lung burden from 1 h to 56 days post exposure would provide information concerning the slow phase
of clearance. Lungs with associated lymph nodes (whole
lungs) were harvested from nanoparticle-exposed mice, as
well as, ambient air control mice, snap frozen in liquid nitrogen, and stored at −80 °C. CoO or La2O3 nanoparticle
lung burden was determined by Elemental Analysis, Inc.
(Lexington, KY) using instrumental neutron activation
analysis (INAA). Briefly, lung samples were exposed to a
thermal neutroflux of 5 × 103 n/cm2/s for 24 h to produce
radioactive Co or La. The radioactive emission from the
samples was measured by gamma-ray spectroscopy. The
intensity of emissions for these lung samples was compared to spiked samples and is indicative of the amount of
the Co or La present in the lung.
Bronchoalveolar lavage

At 1, 7 and 56 days post exposure, mice were euthanized
by i.p. injection of sodium pentobarbital (>100 mg/kg
body weight). These post exposure times were chosen to
determine if lung damage and inflammation were transient or more prolonged as determined by markers in
bronchoalveolar lavage (BAL) samples as described
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previously [14]. BAL of the whole lung was performed
by inserting a cannula into the trachea and lavaging with
Ca2+ and Mg2+ free phosphate-buffered saline, pH 7.4
with the addition of 0.55 mM D-glucose (PBS). The initial whole lung lavage was performed twice using 0.6 mL
PBS. The subsequent lavages were performed using a
1 mL aliquot per lavage until a total collection volume
of 4 mL PBS was obtained. BAL cells were collected
through centrifugation (1,500 × g, 5 min, 4 °C) of the
first and subsequent lavages, cell pellets were combined,
washed with 1 mL PBS, and centrifuged (1,500 × g,
5 min, 4 °C). BAL cells were re-suspended with 250 μL
PBS and total cell counts were determined using a
Coulter Counter (Multisizer 4, Beckman Coulter, Brea
CA). Cytospins of the BAL cells were generated using a
Shandon cytospin 4 (Thermo Fisher, Waltham, MA) and
stained with modified Wright stain (Thermo Fisher,
Waltham, MA). Cytospins were analyzed for cell differentials using an Olympus DP73 light microscope
(Tokyo, Japan) and analyzed using the Olympus CellSens
Dimension program (Tokyo, Japan). A total of 200 cells
per slide were counted. The total number of each cell
type was determined from total cell counts previously
determined. The supernatant of the first lavage was collected after centrifugation and used for lactate dehydrogenase (LDH) levels and cytokine/chemokine analysis.
BAL fluid LDH measurement

BAL fluid (BALF) was analyzed for lactate dehydrogenase (LDH) activity, a measure of cytotoxicity, using a
COBAS MIRA Plus (Roche Diagnostic Systems, Montclair, NI) as previously described [14]. Samples (never
frozen) were assayed via manufacturer’s protocol where
the chemical oxidation of LDH to pyruvate coupled with
the reduction of NAD+ was measured at 340 nm.
BAL fluid cytokine and chemokine measurement

BALF from 1, 7, and 56 post exposure day mice was
used to analyze cytokine and chemokine expression
as previously described [14] with the following modifications. Samples were processed with the V-Plex
pro-inflammatory Panel (mouse) kit (Meso Scale Discovery, Gaithersburg, MD) using the manufacturer
guidelines. Samples were run in duplicate. The following cytokine/chemokines were analyzed: interferon
gamma (IFN-γ), interleukin-10 (IL-10), interleukin-12
(IL-12p70), interleukin-1 beta (IL-1β), interleukin-2
(IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5),
interleukin-6 (IL-6), neutrophil-activating protein 3
(KC/GRO), and tumor necrosis factor-alpha (TNFα).
Fixation and sectioning of lung tissue

At 1, 7, and 56 days post exposure, mice from the 10
and 30 mg/m3 groups were euthanized by an i.p.
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injection with sodium pentobarbital (>100 mg/kg body
weight) followed by exsanguination. These time points
provide histopathological information concerning the
time course of particle-induced inflammation. The slow
development of fibrosis would be evaluated by collagen
staining of lung tissue at 56 days post exposure. The left
lung was inflated with 0.5 mL 10 % neutral buffered formalin. Tracheobronchial lymph nodes were taken from
1 and 56 day post exposure mice from the air control
and 30 mg/m3 CoO or La2O3 nanoparticle groups and
fixed with 10 % neutral buffered formalin. Sections of
the left lung and the tracheobronchial lymph nodes were
processed, embedded in paraffin, cut at 5 microns and
stained with hematoxylin and eosin (H&E) for microscopic analysis. Sections of the left lung were also
stained with Masson’s trichrome and Sirius red for fibrosis evaluation. Stained slides were sent to Integrated
Laboratory Systems, Inc. (Research Park Triangle, NC) for
histopathological analysis. Results were peer reviewed by a
veterinary pathologist at NIOSH (Morgantown, WV). Images were captured using an Olympus BX53 microscope
equipped with a DP73 camera.
Enhanced-darkfield light microscopy imaging of
nanoparticles

CoO and La2O3 nanoparticles in sections from exposed
lungs and tracheobronchial lymph nodes were assessed
using an enhanced-darkfield optical system as described
previously [14]. Although these nanoparticles have dimensions less than the wavelength of light, they have closely
packed atoms, and thus typically have a refractive index
significantly different from that of biologic tissues and/or
mounting medium. These characteristics produce significantly greater scattering of light by nanoparticles, which
then appear as bright particles compared to the surrounding tissues. As described previously, this method of imaging can be used to scan lung sections at relatively low
magnification to identify nanoparticles that would not be
detected by other means [13–16].
The optical system for detection of nanoparticles consisted of high signal-to-noise, darkfield-based illumination optics adapted to an Olympus BX-41 microscope
(CytoViva, Auburn, AL). Sections for darkfield examination were specifically cut from paraffin blocks and collected on ultrasonically cleaned, laser cut slides (Schott
North America Inc, Elmsford, NY) to avoid nanoparticle
contamination from the ground edges of traditional
slides. After staining with Sirius red-hematoxylin, sections were coverslipped with Permount. After alignment
of the substage oil immersion optics with a 10× objective,
sections were examined with 60× air or 100× oil
immersion objectives. Enhanced darkfield images were
taken with a 2048 × 2048 pixel digital camera (Dage-MTI
Excel digital camera XLMCT, Michigan City, IN).
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Statistics

Statistical comparisons for CoO and La2O3 nanoparticle
exposed groups, separately, across three concentrations
including air controls were performed separately for
each of three post exposure times using analysis of variance (ANOVA). Since variance estimates were different
across treatment groups, the ANOVA models were estimated using an unequal variance method available from
SAS PROC MIXED [17]. Similarly, comparisons across
exposure times for each concentration were performed
using unequal variance ANOVA. All statistical tests were
two tailed with the significance level set to 0.05.

Results
Aerosol particle characterization

Exposure chamber aerosol samples were collected by
drawing particles from the chamber through several
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aerosol instruments. The mass median aerodynamic diameters of the CoO and La2O3 nanoparticles were determined by a cascade impactor (MOUDI Models 110-R,
MSP Corp, Shoreview, MN), which fractionates the particles into 10 size ranges from 56 nm to 18 μm. Results
are depicted in Fig. 1a and b. The mass median aerodynamic diameter of CoO nanoparticles was determined
to be 2.16 μm with a geometric standard deviation of
2.95. The mass median aerodynamic diameter of La2O3
nanoparticles was determined to be 2.26 μm with a geometric standard deviation of 2.02. The count median
aerodynamic diameters of the CoO and La2O3 nanoparticles were measured using a Scanning Mobility Particle
Sizer (SMPS model, TSI Inc, Shoreview, MN). These
data are depicted in Fig. 1c and d. The median mobility
equivalent diameter was 259 nm for CoO nanoparticles
and 348 nm for La2O3 nanoparticles, with geometric

Fig. 1 Aerosol particle characterization. Mass median aerodynamic diameter of a CoO and b La2O3 nanoparticles measured by a cascade
impactor (MOUDI). Count median aerodynamic diameter of c CoO and d La2O3 nanoparticles measured by a scanning mobility particle sizer.
FESEM of aerosolized e CoO and f La2O3 nanoparticles from the whole-body inhalation chamber
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standard deviation of 1.65 nm and 1.53 nm for CoO and
La2O3 nanoparticles, respectively. Aerosol samples were
collected on 25 mm polycarbonate filters with 0.2 μm
diameter pores (EMD-Millipore, Billerica, MA) at a rate
of 1 L/min. Particle imaging was performed using these
filter samples of CoO and La2O3 nanoparticles with a
field emission scanning electron microscope (FESEM;
JEOL 6400, JEOL Inc) (Fig. 1e and f, respectively).
Lung burden and clearance of CoO and La2O3
nanoparticles

Lungs, consisting of the lower trachea, lung lobes and
lymph nodes, were analyzed to determine the whole
lung burden of CoO and La2O3 nanoparticles by INAA
at 1 h after completion of the inhalation exposure. As
seen in Fig. 2, mice exposed to CoO and La2O3 nanoparticles at 10 mg/m3 had an initial whole lung burden of
7.7 μg/lung and 30.1 μg/lung, respectively. At 30 mg/m3,
CoO nanoparticle-exposed mice had a whole lung burden
at 1 h post exposure of 18.7 μg/lung, while La2O3
nanoparticle-exposed mice had a whole lung burden of
77.5 μg/lung 1 h after exposure. To determine nanoparticle clearance, whole lungs from mice exposed to the low
or high particle doses were examined at 56 days post exposure. CoO nanoparticles were rapidly cleared, to the extent that <1 % of the nanoparticles remained in the lung
plus lymph nodes at both exposure concentrations. However, for La2O3 nanoparticles, 22 and 50 % of the particles
remained in the lung and lymph nodes 56 days after low
and high dose exposures to La2O3 nanoparticles, respectively. These data indicate considerable differences in the
rate of CoO and La2O3 nanoparticle clearance.
To further investigate the lung burden and clearance
of CoO and La2O3 nanoparticles, enhanced-darkfield
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light microscopy was used to analyze the lungs and tracheobronchial lymph nodes for nanoparticle deposition
and accumulation in lymph nodes in mice exposed at
30 mg/m3. CoO and La2O3 nanoparticles were present
in the lung tissue at 1 day post exposure (Fig. 3). An
equal amount of La2O3 nanoparticles was found in the
alveolar macrophages when compared to the CoO nanoparticles; however, more La2O3 nanoparticles were seen
in the interstitium at 1 day post exposure, reflecting a
higher lung burden 1 h post exposure and more translocation of La2O3 nanoparticles. These data correlated
with the whole lung burden results measured by INAA,
indicating greater clearance of CoO nanoparticle than
the La2O3 nanoparticles. Therefore, the tracheobronchial
lymph nodes were analyzed (Fig. 4). Results showed that
the lymph nodes had no CoO nanoparticles, but showed
some scattered La2O3 nanoparticles at 1 day post exposure. Furthermore, the lymph nodes of mice exposed to
La2O3 nanoparticles at 56 days post exposure showed
abundant nanoparticles, supporting migrating of La particles from the interstitium to the lymphatics. In contrast, the lymph nodes of only 2 of the 5 animals
examined showed a few scattered CoO nanoparticles at
56 days post exposure. In the conducting airways, it was
observed that the CoO nanoparticles were cleared very
rapidly (data not shown), while the La2O3 nanoparticles
accumulated in the airway epithelium at 1 day post exposure for the high-dose exposure group (Fig. 5). Therefore, CoO nanoparticles depositing on the conducting
airways appear to be cleared rapidly during the 4 day inhalation exposure by the mucocillary escalator, while
La2O3 nanoparticles clearance from the conducting airways are inhibited by rapid uptake by airway epithelial
cells. These enhanced darkfield results support the

Fig. 2 Whole lung burden and clearance of CoO and La2O3 nanoparticles. Lungs and associated lymph nodes from mice were analyzed by INAA
for initial whole lung burden (1 h post exposure on day 4) and lung clearance (56 days post exposure) for CoO and La2O3 nanoparticles at 10 and
30 mg/m3. Values are presented as μg of nanoparticle per weight of lung. n = 5 male mice per group. *p < 0.05 represents significance between air
control and CoO or La2O3 nanoparticle-exposed mice. # p < 0.05 represents significance between CoO and La2O3 nanoparticle-exposed mice
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Fig. 3 Enhanced-darkfield images-lung deposition. Representative images of lungs from mice 1 and 56 days after exposure to 30 mg/m3 illustrate
the lung burden and clearance of nanoparticles from the lung. n = 6 male mice per group. Nanoparticles are identified by white arrows

INAA data showing that the whole lung burden of CoO
nanoparticles 1 h post exposure is lower than that of
La2O3 nanoparticles. Additionally, La2O3 nanoparticles
appear to translocate to tracheobronchial lymph nodes,
resulting in relatively high whole lung burdens at 56 days
post exposure.

similar transformation in the lung [6] and proposed that
the accompanying insolubility of the LaPO4 may be responsible for slow clearance of these particles, allowing
their translocation across the epithelial layer to the interstitium and from there to the regional lymph nodes.
Pulmonary damage and inflammation

Transformation of La2O3 nanoparticles in phagolysosomal
simulated fluid (PSF)

As we reported previously, exposure of differentiated
THP-1 macrophages to La2O3 nanoparticles (50 μg/ml)
resulted in engulfment and incorporation of these nanoparticles into phagolysosomal vesicles after 6 h in culture
[6]. Suspension of La2O3 nanoparticles in an acidic PSF
for 24 h resulted in a change in nanoparticle morphology from spheres to a sea-urchin-like shape (Fig. 6a).
This morphological transformation is associated with a
chemical modification of the nanoparticle from La2O3 to
LaPO4 as determined by XRD (Fig. 6b). In contrast,
CoO nanoparticles do not undergo phosphate complexation and do not undergo transformation. We have previously demonstrated that La2O3 nanoparticles undergo

LDH activity in BALF was used as a measure of
nanoparticle-induced pulmonary damage at days 1, 7
and 56 post exposure. Figure 7a shows that CoO and
La2O3 nanoparticles induce significant LDH release at 1
and 7 days post-exposure compared to the air-only control, but returned to basal levels by 56 days post exposure for both low- and high-dose exposures. When
comparing CoO and La2O3, CoO nanoparticles resulted
in significantly higher LDH levels 1 day after the 10 mg/
m3 exposure than La2O3 nanoparticles. However, there
were no further differences between these nanoparticles
for low-dose exposures at all other post-exposure times.
When comparing the impact of high-dose exposures,
CoO nanoparticles significantly increased LDH levels at
1 day post exposure compared to La2O3 nanoparticles,

Fig. 4 Enhanced-darkfield images- tracheobronchial lymph nodes. Representative images of tracheobronchial lymph nodes from mice 1 and
56 days post exposure to 30 mg/m3 illustrate the initial lung burden and accumulation of nanoparticles in the tracheobronchial lymph nodes. n = 6
male mice per group. Nanoparticles are identified by white arrows
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Fig. 5 Enhanced-darkfield images-airway epithelium. Representative
images of the accumulation of La2O3 nanoparticles in the airway
epithelium from mice at 1 day post exposure to 30 mg/m3. n = 6 male
mice per group
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but this position was reversed at 7 days post exposure,
when La2O3 nanoparticles induced greater LDH release
compared to CoO nanoparticles. There were no significant differences between nanoparticle-exposed groups
and the air control at 56 days post inhalation for both
low and high exposure levels.
Pulmonary inflammation was determined as polymorphonuclear leukocytes (PMNs) calculated from total
BAL cell counts and cell differentials of BAL samples
from exposed mice. As seen in Fig. 7b, PMNs were significantly elevated at 1 and 7 days post exposure for
low-dose exposure to both particle types compared to
the air-only control. While the PMNs cell count was
higher in La2O3 nanoparticles compared to CoO
nanoparticle-exposed animals at 1 and 7 days post exposure, the counts returned to background levels at
56 days post-exposure. The same pattern was seen for
high-dose exposures on days 1 and 7 days post exposure.
However, 56 days after the high-dose La2O3 nanoparticles exposure, a significant increase in the BALF PMNs

Fig. 6 Transformation of La2O3 nanoparticles in phagolysosomal simulated fluid (PSF). a TEM images and b XRD spectra of La2O3 nanoparticles
after PSF exposure. La2O3 nanoparticles were suspended in H2O or PSF at 50 μg/mL and incubated at 37 °C for 24 h. After washing in H2O, the
morphological and crystal structure changes in La2O3 nanoparticles were examined by TEM and XRD, respectively
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Fig. 7 Pulmonary damage and inflammation. BALF was analyzed for a lactate dehydrogenase activity and cell differentials from mice exposed to
air control, CoO or La2O3 nanoparticles at 1, 7 and 56 day post exposure. b PMNs, c alveolar macrophages, d lymphocytes, and e eosinophils
were counted from each BAL cytospin. Values are mean ± standard error. n = 4 mice per group. * p < 0.05 represents significance between air
control and CoO or La2O3 nanoparticle-exposed mice. # p < 0.05 represents significance between CoO and La2O3 nanoparticle-exposed mice

cell counts persisted when compared to the air-only
control. This was not the case for high-dose exposure
to CoO nanoparticles. Figure 7c indicates that there
were increased numbers of alveolar macrophages during low-dose exposure to both particle types at day 1
and 7 post-exposure, as well as, after 1, 7 and 56 days
following exposure to 30 mg/m3 to both particle
types. When comparing the number of alveolar macrophages in CoO and La2O3 nanoparticle-exposed

BAL samples, La2O3 nanoparticles had significantly
higher counts at 1 and 7 day post exposure at the
low exposure and at 1 and 56 day after the higher exposure level. Figure 7d demonstrates that low-dose
CoO nanoparticles exposure induced higher lymphocyte cell counts at 1 day post exposure, as well as, on
days 1 and 7 following high-dose exposure. La2O3
nanoparticles induced increased lymphocyte cell
counts on days 1 and 7 after low-dose exposure and
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on days 1, 7 and 56 after high-dose exposure. CoO and
La2O3 nanoparticles also induced elevated eosinophils
levels on days 1 and 7 following both low-and high-dose
exposures. Eosinophils levels remained elevated 56 days
after high-dose La2O3 nanoparticles exposure (Fig. 7e).
When contrasting the induction of eosinophils between
CoO and La2O3 nanoparticles, it was determined that
La2O3 nanoparticles induced higher counts at days 1 and
7 in response to low-dose exposure, as well as 1 and
56 days after high-dose exposure. In summary, these data
indicate that while both CoO and La2O3 nanoparticles induced acute pulmonary inflammation, only La2O3 nanoparticles induced a chronic inflammatory response with
an increased recruitment of a spectrum of inflammatory
cells when compared to both air control and CoO
nanoparticle-exposed mice.
CoO and La2O3 nanoparticle-induced cytokine production

Ten different cytokines were examined in the BALF
of mice exposed to low and high doses of CoO and
La2O3 nanoparticles, and sacrificed at 1, 7 and 56 days
post exposure. Four cytokines showed significant differences from the air-only control. This includes increased release of IL-1β in the BALF on days 1 and 7
after high-dose exposure to both nanoparticle types
(Fig. 8a). IL-1β levels were higher 1 day after CoO
nanoparticles exposure compared to La2O3 nanoparticles. However, the opposite was seen after 7 days,
with La2O3 nanoparticles inducing the greater response. After 56 days, there were no increases in IL-
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1β levels for either nanoparticle type. In order to elucidate the possible explanation for the differences in
sustained in vivo IL-1β production in response to the
different particle types, we performed an in vitro
study with differentiated THP-1 macrophages. We have
previously demonstrated that upon differentiation of this
myeloid cell line, THP-1 cells attain macrophage-like
properties. Therefore, differentiated THP-1 macrophages
have commonly been used to assess responses of pulmonary macrophages to a number of engineered nanoparticles. Since both CoO and La2O3 nanoparticles
have been shown by our lab to be engulfed by
differentiatedTHP-1 macrophages and become associated with phagolysosomes [6], we assessed whether
there is a difference in their ability to induce lysosomal
damage by using a Magic Red-labeled substrate for the
lysosomal enzyme, cathepsin B. As shown in Fig. 9a,
both non-treated, as well as, CoO nanoparticle-treated
cells exhibit a punctate distribution of Magic Red,
which is confined to intact lysosomes. However, in the
case of La2O3 nanoparticle-treated cells, the dye could
be seen to spread diffusely to the cytosol, indicating
lysosomal damage. Lysosomal damage, as well as the
release of cathepsin B are known stimuli that lead to
the assembly of the NLRP3 inflammasome, which is responsible for cleavage of pre-IL-1β to IL-1β. Accordingly, we also found that in vitro exposure to La2O3
nanoparticles induced a significant increase in IL-1β
production compared to CoO nanoparticles, which induced little effect (Fig. 9b).

Fig. 8 CoO and La2O3 nanoparticle-induced pro-inflammatory response in BALF. a IL-1β, b TNFα, c IL-6 and d KC/GRO were all analyzed in the
BALF of exposed mice. The measurement of cytokines was performed on BALF at both doses and all time points. Values are mean ± standard
error. n = 4 mice per group. * p < 0.05 represents significance between air control and CoO or La2O3 nanoparticle-exposed mice. # p < 0.05 represents
significance between CoO and La2O3 nanoparticle exposed mice
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Histopathology

Fig. 9 Lysosomal damage, cathepsin B release and IL-1β production
in THP-1 cells. THP-1 cells were incubated with 50 μg/mL CoO
or La2O3 nanoparticles for 6 h. Then cells were stained with Magic
Red-labeled cathepsin B substrate and visualized by confocal microscopy (a). IL-1β production was assessed by ELISA after THP-1 cells were
treated with 0–100 μg/mL CoO or La2O3 nanoparticles for 24 h. (b)

TNFα (Fig. 8b) was significantly elevated at 1 and 7 days
post exposure for both nanoparticle types at low and high
doses, compared to the air-only control. Moreover, the
levels remained higher than control for up to 56 days following the high-dose La2O3 nanoparticles exposure. La2O3
nanoparticles induced higher TNFα level than CoO nanoparticles 1 day after low-dose exposure and 7 days after
high-dose exposure. IL-6 (Fig. 8c) was increased at 1 day
after the low-dose exposure and days 1 and 7 following
high-dose exposure for both nanoparticle types. CoO
nanoparticles induced a bigger response than La2O3 nanoparticles 1 day after exposure, while La2O3 nanoparticles
induced the greater response 7 days after high-dose exposure. KC/GRO (Fig. 8d) was significantly elevated by CoO
nanoparticles at 1 and 7 days after both exposure levels.
La2O3 nanoparticle induced KC/GRO expression at 1 and
7 days after both exposure levels and at 56 days after the
high exposure compared to air control. When comparing
the particle responses, low-dose La2O3 nanoparticles induced greater KC/GRO expression than CoO nanoparticles at 1 and 7 days post exposure, as well as at all time
points after high-dose exposure. Taken together, these data
suggest that the different expression patterns of proinflammatory cytokines and chemokines in the BALF of
mice exposed to CoO and La2O3 nanoparticles may lead to
different modes of pulmonary damage and inflammation.

Mouse lungs were analyzed histologically after animal
sacrifices on days 1, 7, and 56 following low and highdose exposures to both particle types. There were no significant pathological changes observed at low exposure
levels (data not shown). However, after high-dose exposure, we observed an increase in the number of alveolar
macrophages in response to CoO nanoparticles inhalation at 1 and 7 days post exposure, which returned to
air-only control levels by day 56. In contrast, the number
of alveolar macrophages in lungs of La2O3 nanoparticleexposed mice increased progressively from day 1 to day
7 post exposure and remained elevated for up to 56 days
post exposure (Fig. 10).
There was no prominent interstitial fibrosis observed in
the lungs of animals exposed to CoO nanoparticles 56 days
after inhalation exposure. In contrast, minimal fibrosis
was occasionally seen in the lungs of animals exposed to
La2O3 nanoparticles 56 days post exposure (Fig. 11). This
fibrosis was localized to areas of inflammation, suggesting
collagen deposition at sites of macrophage activation and
cytokine release. Infrequent observations in the lung tissue
of the La2O3 nanoparticle-exposed animals, included epithelial hyperplasia of bronchioles and alveoli, vasculitis

Fig. 10 Histopathology. Lungs of mice exposed to 30 mg /m3 CoO
or La2O3 nanoparticles or air control were stained with H&E. n = 12
mice per group
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Fig. 11 Interstitial fibrosis in lungs of La2O3 nanoparticle-exposed mice. Higher power magnification and Picrosirius red (PSR) staining demonstrate a
small focus of interstitial fibrosis in a La2O3 nanoparticles exposed animal at 56 days post exposure. n = 12 male mice per group

(data not shown), and pleural fibrosis (Fig. 11). There were
no observable differences seen in the lungs of CoO
nanoparticle-exposed mice at 56 day post exposure
compared to air control (data not shown).

Discussion
The present study determined pulmonary responses to
inhalation exposure to CoO and La2O3 nanoparticles.
Exposures were 6 h/day for 4 days to 10 mg/m3 or
30 mg/m3. Lung burden was measured at 1 h and
56 days post-exposure to evaluate clearance. Bronchoalveolar lavage was conducted to evaluate lung damage
(LDH) and inflammation (cell differentials and cytokines) at 1, 7, and 56 days after inhalation exposure. Enhanced darkfield microscopy was conducted at 1 and
56 days post exposure to determine initial deposition
and time-dependent translocation of the nanoparticles.
Histopathologic analysis determined the degree of pulmonary inflammation and fibrosis at 1, 7, and 56 days
after inhalation exposure to these nanoparticles.
Inhalation of CoO nanoparticles resulted in acute pulmonary damage and inflammation with BAL levels of
LDH and inflammatory mediators peaking at 1 day postexposure (Figs. 7 and 8). Likewise histopathologic results
indicate an alveolar macrophage inflammatory response,
which peaked at 1 day after inhalation of CoO nanoparticles (Fig. 10). In contrast, pulmonary responses to
inhalation of La2O3 nanoparticles were more persistent
than after CoO nanoparticles exposure. Indeed, LDH
activity of BALF and levels of inflammatory mediators
peaked at 7 days post exposure (Figs. 7 and 8), and
histopathology indicated that mild histocytosis was
found in La2O3 nanoparticle-exposed lungs at 56 days

after inhalation exposure. In addition, La2O3 nanoparticles
exposure resulted in a mild fibrotic response (Fig. 11).
In summary, the present data concerning pulmonary
responses 56 days after in vivo exposure suggest that inhalation exposure to La2O3 nanoparticles was more
fibrogenic and caused more persistent inflammation
than CoO nanoparticles at equivalent aerosol exposure
levels. In comparison, our previous in vitro assays of
cytotoxicity and induction of oxidative stress reported
that CoO nanoparticles were substantially more potent
than La2O3, supporting predictions from band gap theory [3, 7]. Additionally, our short term (1 day post) oropharyngeal aspiration study in mice reported that CoO
nanoparticles caused a greater acute inflammatory response, supporting the conclusion from in vitro studies
[3]. It is likely that differences between our previous in
vitro and acute (1 day post exposure) in vivo studies and
those of the present longer term (56 day post-exposure)
4 day inhalation exposure study are due to differences in
the clearance rates for these two nanoparticles. Measurement of lung burdens 1 h after the end of the 4 day
inhalation exposure indicate that burdens for CoO nanoparticles were only 25 % of those for La2O3 nanoparticles
at both the low (10 mg/m3) and high (30 mg/m3) exposure
levels, i.e., lung burdens of 7.7 and 18.7 μg vs. 30.1 and
77.5 μg for CoO and La2O3 nanoparticles, respectively.
These differences in lung burdens at the start of the post
exposure observation period would not have been predicted by the lung deposition vs particle aerodynamic
diameter data reported by Raabe et al. [18] for mice, since
aerosol levels and mass median aerodynamic diameters
(MMADs) for CoO and La2O3 nanoparticles were nearly
identical for these inhalation exposures (Fig. 1). Of note,
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estimations from the Raabe et al. data predicts that as
high as 60 % of lung deposition of particles with
MMADs of 2 μm would be in the tracheobronchiolar
region of the mouse lung, with the remaining 40 %
depositing in the alveolar region of the lung [18]. Enhanced darkfield microscopy at 1 day post exposure indicates that CoO nanoparticles were rapidly cleared from
the conducting airways during the 4 day inhalation period
by the mucocillary escalator, which exhibits a half time for
clearance of a few hours. However, enhanced darkfield microscopy indicates that 1 day after inhalation exposure the
La nanoparticles had translocated from the surface of the
conducting airways into bronchial epithelial cells (Fig. 5c),
thus, escaping mucocillary clearance. This emphasizes that
calculated lung deposition does not always reflect actual
particle lung burdens, and that measurement of lung burden is essential to correctly interpret pulmonary response.
Our previous in vitro [7] and 1 day post-aspiration in vivo
[3] studies would not be able to discern this clearancedependent difference in initial lung burden of CoO
and La2O3 nanoparticles; thus, they would fail to predict the greater sub-chronic inflammatory and fibrogenic potential of La2O3 vs. CoO nanoparticles found
in the present study.
As discussed above, lung burden 1 h after the 4 day
exposure was greater for La than Co metal oxide nanoparticles, reflecting predominant rapid clearance of CoO
nanoparticles by the mucocillary escalator. Concerning
the slow phase of clearance, whole lung burden for La
nanoparticles was also greater than that for CoO nanoparticles at 56 days post-exposure, where persistent
whole lung burden was 6.6 μg and 38.8 μg for the low
and high level of La2O3 nanoparticles, respectively, compared to < 1 % of the 1 h post exposure lung burden for
CoO nanoparticles. There are two different slow pulmonary clearance mechanisms: 1) uptake of the nanoparticles deposited in the respiratory zone by alveolar
macrophages and slow migration of these particle-laden
cells to the mucocillary escalator, or 2) translocation of
the nanoparticles across epithelial cells into the interstitium and slow clearance through the lymphatic system
[19]. Upon analyzing the enhanced darkfield images, the
CoO nanoparticles deposited in the respiratory zone
were seen mainly in alveolar macrophages at 1 day postexposure, suggesting slow clearance via migration to the
mucocillary escalator (Fig. 3). However, a large amount
of the La nanoparticles were seen in epithelial cells and
the interstitium of the airways at 1 day post exposure
(Figs. 3 and 5) and in the lymphatic system by 56 days
post exposure (Fig. 4). In contrast, very few CoO nanoparticles were detected in the tracheobronchial lymph
nodes of exposed mice at 56 days post inhalation. The
difference in pulmonary fate and clearance mechanism
for Co and La nanoparticles would result in the
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observed differences in pulmonary responses reported in
the present study.
Mechanistic non-animal studies do shed light upon the
results of the present mouse inhalation study. For example, we have reported that La2O3 nanoparticles were
present within phagolysosomes of differentiated THP-1
macrophages after a 6 h exposure in culture [6]. Additionally, we showed that La2O3 nano-spheres transform into
sea urchin-shaped LaPO4 particles after a 24 h incubation
in an acidic PSF, and such sea urchin-shaped particles
were found in the differentiated THP-1 macrophages 12 h
after in vitro exposure to La2O3 nanoparticles. Associated
with this transformation of La nanoparticles was rupture
of lysosomal membranes, demonstrated by the cytosolic
release of cathepsin B into the cytoplasm of differentiated
THP-1 macrophages 12 h after in vitro exposure to La2O3
nanoparticles [6]. Our lab has also shown that rupture of
lysosomes in alveolar macrophages was observed 40 h
after exposure of mice by aspiration of La2O3 nanoparticles [6]. Therefore, it is feasible that in the present inhalation study that La2O3 nanoparticles were transformed
upon engulfment by alveolar macrophages, ruptured phagolysosomes, escaped these phagocytes, and entered bronchial epithelial cells, thus, avoiding clearance by the
mucocillary escalator. CoO nanoparticles, in contrast to
La2O3, did not undergo such transformation, since they
did not lyse lysosomes (Fig. 9). Therefore, CoO nanoparticles would remain in macrophages and be cleared.
Mechanistic in vitro studies also predict the fibrotic
response to La2O3 nanoparticles exposure observed in
the present inhalation study. Indeed, Fig. 9b shows that
in vitro exposure of THP-1 macrophages to La2O3 nanoparticles for 6 h activated the NLRP3 inflammasome as
indicated by a substantial, dose-dependent release of IL1β with La2O3 nanoparticles, while CoO nanoparticles
failed to induce IL-1β production. Activation of the
NLRP3 inflammasome has been linked with pulmonary
fibrotic diseases, such as silicosis and asbestosis [20, 21].
In addition, IL-1β has been shown to activate fibroblasts
and cause pulmonary fibrotic responses [22–24]. The
present study indicates that inhalation of La2O3 nanoparticles caused a 9 fold greater Il-1β production 7 days
after inhalation than the non-fibrotic CoO nanoparticles
inhalation (Fig. 8a).
Of interest, our longer term (21 day post exposure)
aspiration study in mice did observe NLRP3 inflammasome activation (2.4 fold increase in BALF levels of IL-1β)
and pulmonary fibrosis in response to La2O3 nanoparticles [6]. This indicates that when lung burdens are
similar, results of bolus particle exposure studies can be
predictive of more costly and technically more complex
inhalation studies. Therefore, there is an important role
for pulmonary bolus exposure studies (oropharyngeal
aspiration and intratracheal instillation) in a tiered
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approach to hazard ranking and assessment for
nanoparticles.
In addition to IL-1β, other mediators have been associated with fibrogenesis. TNF-α has been demonstrated to
play a key role in activating molecular pathways leading
to pulmonary fibrosis [25–27]. In the present study, we
found that La2O3 nanoparticles inhalation at 30 mg/m3
caused a 6 fold greater production of TNF-α than CoO
nanoparticles at 7 days post exposure (Fig. 8b). Previously, we reported that aspiration of La2O3 nanoparticles
induced a 2 fold increase in BALF levels of TGF-β1 and
PDGF, mediators associated with pulmonary fibrogenesis, 21 days post exposure in mice [6]. This was associated with a 67 % increase in lung collagen.
In the present study, the lung burden of La2O3 nanoparticles 1 h after a 4 day inhalation of 30 mg/m3 was
77.5 μg/whole lung. In our previous oropharyngeal aspiration study, lung burden was 50 μg/lung [6]. It should
be noted that such lung burdens are lower than those
necessary to cause volumetric overload and impairment
of clearance [28]. Indeed, alveolar macrophages were not
overloaded with particles (Fig. 3), and inhalation of an
equal aerosol exposure dose of CoO nanoparticles did
not result in delayed clearance.
An issue is the relevance of these pulmonary doses of
La2O3 nanoparticles to expected worker exposure. Unfortunately, no worker exposure data for nano-La2O3 are
available. To date, the only Recommended Exposure
Limit (REL) for a nano metal oxide is 0.3 mg/m3 proposed
for nano TiO2 [29]. Assuming this level of airborne La2O3
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nanoparticles in a workplace, workers would be expected
to achieve a lung burden, normalized to an equivalent burden per lung surface area, similar to the mice in these
studies in approximately 1 year. Therefore, our studies are
relevant to feasible worker exposure.
In the present study, the physical chemical transformation of La2O3 nanospheres to LaPO4 urchin-shaped
particles is proposed to be related to the interstitial accumulation of La and fibrosis. Of interest, it has recently
been reported that CeO2 transforms into urchin-shaped
phosphate Ce nanoparticles in vivo [30]. This may explain why CeO2 nanoparticles exhibit low in vitro cytotoxicity, yet induce pulmonary fibrosis in a rat model
[31]. In light of these findings, further investigation into
the phosphation of certain nano metal oxides and resultant alterations in the bioactivity of these transformed
particles is warranted.
We have proposed high throughput in vitro screening
as an essential component of a tiered testing approach
for nanoparticles [11]. Prudent selection of in vitro assays to identify adverse outcome pathways (AOPs) produces potency and mechanistic data in a rapid and low
cost manner. Such data can be used for hazard ranking.
In addition, in vitro testing can provide guidance concerning which in vivo responses to evaluate. We do not
propose use of in vitro data for quantitative risk assessment, since in vitro assays use doses/cell surface area
much higher than dose anticipated in the human lung
per alveolar epithelial surfaces area. However, when
carefully conducted, in vitro results have been able to

Fig. 12 Schematic image showing the toxicity mechanisms of CoO and La2O3 nanoparticles. The redox potential of CoO nanoparticles falls into
the biological redox potential (BRP), which allows electrons to transfer from biological molecules to CoO nanoparticles. This process could induce
oxidative stress, leading to mitochondria damage, cell death and acute lung toxicity. In contrast, no electrons were transferred from biological
system to La2O3 nanoparticles. However, La2O3 nanoparticles could transform into sea urchin LaPO4 in lysosomes, induce lysosomal damage,
cathepsin B release, NLRP3 inflammasome activation and IL-1β production, which finally results in chronic lung inflammation and fibrosis
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predict in vivo response to nanoparticles, such as carbon
nanotubes and metal oxides [6, 32]. In the present study,
doses/culture cell surface area were much higher than
lung burdens normalized to the alveolar surface in the
mouse. However, in vitro studies did produce mechanistic information useful to interpret the differences in
clearance of fibrotic responses of mice after inhalation of
CoO and La2O3 nanoparticles.

whole-body inhalation exposure. RRM performed enhanced darkfield analysis
of samples. JS, ALM, LB, MW and DSB helped with in vivo experiments. MO
performed histopathology analysis. BTC performed exposure chamber calculations and experimental design for whole-body inhalation exposures. MEA
performed statistical analysis. DWP, VC, AN, and YQ contributed intellectually
to the project design and in writing the manuscript. All authors read and approved the final manuscript.

Conclusion
In summary, results from the present study as well as
previous studies indicate that a tiered approach is required to predict sub-chronic responses following inhalation of CoO or La2O3 nanoparticles. Simple in vitro
assays for oxidative stress and cell death predict the
acute inflammatory response to CoO nanoparticles in
agreement with the band gap theory. However, they do
not explain the persistent whole lung burden and fibrotic response after inhalation of La2O3 nanoparticles.
More mechanistic in vitro assays associated with biotransformation of La2O3 nanoparticles to LaPO4 and activation of the NLRP3 inflammasome do shed light on
the biopersistent and fibrogenic potential of La2O3
nanoparticles. Lastly, bolus pulmonary exposure studies
involving La2O3 nanoparticles were able to predict the
fibrogenic response seen after inhalation exposure, when
similar exposure doses and post exposure times are
employed. This tiered approach employing relevant adverse outcome pathways for hazard assessment is summarized in Fig. 12.
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